Bispecific Antibodies for the Treatment of Multiple Myeloma

Bispecific antibodies in the treatment of multiple myeloma - Nature

Bispecific antibodies are dual antigen targeting constructs that engage the T cells to plasma cells through various target antigens.

Bispecific Antibodies for the Treatment of Multiple Myeloma - PubMed

Numerous bispecific agents are in clinical development with some on the precipice of regulatory approval. While BCMA remains the principal ...

Bispecific Therapies | International Myeloma Foundation

Bispecific antibodies (also known as bispecifics, or BsAbs) are an immunotherapy (immune cell therapy) showing promising clinical trial results.

Bispecific Antibodies for Multiple Myeloma: Six Things Your Patients ...

In 2022, the drug teclistamab became the first bispecific antibody to be approved by the U.S. Food and Drug Administration (FDA) for the ...

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance ...

Bispecific antibodies represent a new treatment option for patients with myeloma. These antibodies activate the patient's own T-cells to kill their tumour ...

Bispecific Antibodies for Myeloma Treatment

In summary, bispecific antibodies are a novel form of immunotherapy where we can bring together a myeloma cell and a T cell to treat a patient's ...

Bispecific Antibody Use in Patients With Lymphoma and Multiple ...

The current FDA-approved BsAbs for patients with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy are ...

Current use of bispecific antibodies to treat multiple myeloma

This article focuses on the current use of BsAb in MM, reviewing the pre-clinical and clinical studies that support data-driven clinical decisions.

Dr Chari on Currently Available Bispecific Antibodies in Multiple ...

The bispecific antibody most recently approved for patients with relapsed/refractory multiple myeloma is the GPRC5D-targeted agent talquetamab- ...

Bispecific Antibody Therapy in Multiple Myeloma - YouTube

Shonali Midha, MD, discusses opportunities for utilizing bispecific antibodies in treating relapsed/refractory multiple myeloma.

Bispecific Antibodies in Refractory Multiple Myeloma: Basics and ...

In particular, teclistamab, which targets BCMA, has been approved by the FDA for the treatment of relapsed myeloma after 4 lines of therapy.

Bispecific antibodies for the treatment of relapsed/refractory multiple ...

Teclistamab is a bispecific antibody that targets BCMA expressed on the surface of myeloma cells and CD3 on the surface of T cells. In the multicohort phase I/ ...

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for ...

The first bispecific antibody (bsAb) for the treatment of relapsed/refractory multiple myeloma (RRMM), teclistamab, has been approved in 2022.

Infections following bispecific antibodies in myeloma: a systematic ...

Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface ...

T Cell–Redirecting Bispecific Antibodies in Multiple Myeloma

T cell–redirecting bispecific antibodies (BsAb) induce significant responses in heavily pretreated multiple myeloma. BsAbs are currently administered in a ...

Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

It's a bispecific antibody where one of the effectors is binding to CD3, which is on T cells, and the other effector is binding to BCMA, which ...

Bispecific Antibodies in Multiple Myeloma | Dana-Farber ... - YouTube

Omar Nadeem, MD, explains bispecific antibodies as an exciting new immunotherapy treatment option for patients with relapsed or refractory ...

Bispecific Antibodies: Late Side Effects

Bispecific antibodies are advanced immunotherapy drugs that engage immune cells to target and kill myeloma cells. · Side effects of bispecific ...

Use of Bispecifics and CAR-T in Myeloma Treatment - HealthTree

Bispecific antibodies, also known as 'bispecifics' or BsAbs, are a new generation of immunotherapy drugs showing promise in treating multiple myeloma.

Bispecific antibodies in multiple myeloma treatment - Frontiers

Here, we summarize and highlight various bispecific immunotherapies under development in MM treatment, as well as the utility of combining them with current ...